Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Summary

This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA. The study will consist of up to 4-week Screening Period, a 52-week Treatment Period, and a 8-week Safety Follow-up Period.

Timeline

Start

2021-05-06

Primary completion

2023-10-06

Completion

2023-10-06

Publications

• Tang H, Dokoupilova E, Batko B, Zawadzki M, Batalov A, Liu Y, Yang X, Zhou Y, Dong Q, Liu Y. Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study. Expert Opin Biol Ther. 2026 May;26(5):515-524. doi: 10.1080/14712598.2026.2663826. Epub 2026 Apr 28.

Drugs

Indications